Recludix Pharma announced preclinical results for REX-8756, an oral STAT6 inhibitor, showing strong efficacy and safety in models of allergic asthma and dermatitis. The data, presented at two major allergy and dermatology congresses, indicate that REX-8756 effectively blocks STAT6 activation with effects comparable to antibody treatments targeting IL-4/IL-13 pathways. The drug is currently in a Phase 1 clinical trial, with potential to treat inflammatory diseases like atopic dermatitis and asthma. This progress highlights Recludix's innovative approach to developing selective inhibitors for challenging inflammatory targets.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
